Free Trial
NASDAQ:SAVA

Cassava Sciences Q1 2025 Earnings Report

Cassava Sciences logo
$2.38 +0.07 (+3.03%)
Closing price 04:00 PM Eastern
Extended Trading
$2.38 0.00 (-0.21%)
As of 05:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cassava Sciences EPS Results

Actual EPS
-$0.48
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Cassava Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cassava Sciences Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Cassava Sciences' Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled on Thursday, November 6, 2025 at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Cassava Sciences Earnings Headlines

Why More Investors Are Using Family Trusts to Protect Their Wealth
For many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.tc pixel
See More Cassava Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cassava Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cassava Sciences and other key companies, straight to your email.

About Cassava Sciences

Cassava Sciences (NASDAQ:SAVA), a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

View Cassava Sciences Profile

More Earnings Resources from MarketBeat